INDIA
Trivitron and Aloka sign JV Trivitron group of companies, the largest Indian medical technology company and Aloka, the innovators in […]
Tags: biotechnology, care, chennai, Director, GE, India, Japan, Loyola Institute of Business Administration, Malar Hospital, Managing Director, MBA, Mechanical Components Manufacturing, medical technology, Medicare, Premier, Prime Minister, Rs, Trivitron Group, Trivitron group of companies, ultrasound systems, ultrasound technology, Velu
MEDICALL 2011
If one has to pick from a list of successful events which have created a stir within a short span, MEDICALL would turn out to be a winner.
Hospitals use IT to get tough on infections
South Carolina’s 65 acute care hospitals are banding together to prevent healthcare-acquired infections across the state. The effort is expected to save hundreds of lives and as much USD 40 million a year.
NEWS REVIEW – INDIA
[This article was published in the October 2007 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]
News
Trivitron(Chennai, India) and Aloka(Japan) sign JV
Trivitron group of companies, the largest Indian medical technology company and Aloka, the innovators in Ultrasound technology from Japan today announced their joint venture agreement to manufacture cost effective, High Technology Ultrasound equipment in India to suit the needs of the developing countries. The Joint Venture will embark on an Initial investment of about 50 crores by both the companies followed by further investments in due course.
Trivitron and Aloka sign a JV to manufacture high Technology Ultrasound equipment in India
Trivitron group of companies, the largest Indian medical technology company and Aloka, the innovators in Ultrasound technology from Japan today announced their joint venture agreement to manufacture cost effective, High Technology Ultrasound equipment in India to suit the needs of the developing countries. The Joint Venture will embark on an Initial investment of about 50 crores by both the companies followed by further investments in due course.
